Evidence map›Paper›PMID 28139733›Full record

ArticleScientific reports2017

Lysosomal dysfunction and autophagy blockade contribute to IMB-6G-induced apoptosis in pancreatic cancer cells.

Lu Liu, Na Zhang, Yueying Dou, Genxiang Mao, Chongwen Bi, Weiqiang Pang, Xiaojia Liu, Danqing Song, Hongbin Deng

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lu LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Na ZhangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Yueying DouInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Genxiang MaoZhejiang Provincial Key Laboratory of Geriatrics &Geriatrics Institute of Zhejiang Province, Zhejiang Hospital, Hangzhou, Zhejiang 310013, China.
Chongwen BiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Weiqiang PangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Xiaojia LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Danqing SongInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Hongbin DengInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100050, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNZhejiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting the autophagic pathway is currently regarded as an attractive strategy for cancer drug discovery. Our previous work showed that IMB-6G is a novel N-substituted sophoridinic acid derivative with potent cytotoxicity against tumor cells, yet the effect of IMB-6G on autophagy and pancreatic cancer cell death remains unknown. Here, we show that IMB-6G inhibits the growth of MiaPaCa-2 and HupT-3 pancreatic cancer cells and induces caspase-mediated apoptosis, which is correlated with an accumulation of autophagic vacuoles. IMB-6G promotes autophagosome accumulation from the early stage of treatment but blocks autophagic flux in the degradation stage, mainly through attenuation of lysosomal cathepsin activity in pancreatic cancer cells. Moreover, IMB-6G triggers lysosomal membrane permeabilization (LMP), followed by cathepsin B/CTSB and cathepsin D/CTSD release from lysosomes into the cytoplasm. Inhibition of autophagosome formation with siRNA against autophagy protein 5 (Atg5) attenuates IMB-6G-induced LMP and apoptosis. Furthermore, cathepsin inhibitors relieve IMB-6G-induced apoptosis as well. Altogether, our findings demonstrate that IMB-6G is a novel autophagy inhibitor, which induces autophagy-dependent apoptosis through autophagosomal-cathepsin axis in pancreatic cancer cells and indicate the potential value of IMB-6G as a novel antitumor drug candidate.

Indexed as

ApoptosisAutophagyAntineoplastic AgentsAutophagy-Related Protein 5CathepsinsCell Line, TumorHumansLysosomesNitrogen Mustard CompoundsPancreatic NeoplasmsAntineoplastic AgentsATG5 protein, humanAutophagy-Related Protein 5CathepsinsIMB-6GNitrogen Mustard Compounds

Identifiers

PMID28139733
PMCPMC5282566
OpenAlexW2585804334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.